“…This is a determinant factor that limited the pharmacological effects and clinical application of DMY. To improve the bioavailability of DMY, researchers have tried to use DMY in new drug delivery systems such as inclusion complexes (Liu, Ma, et al, 2012;Ruan, Yu, Fu, & Zhu, 2005;Yang, Liu, Liu, & Zhang, 2011), nano-encapsule (Dalcin et al, 2017) or microemulsion (Solanki, Sarkar, & Dhanwani, 2012), co-crystals (Wang, Tong, et al, 2016), phospholipid complexes (Liu, Du, Jie, Chen, & Niu., 2009), and acylation (Cao et al, 2017;Guo, Zeng, Lu, & Shu, 2013;Li et al, 2015;Li, Zheng, & Ning., 2005) to provide higher solubility and bioavailability. In addition, the pharmacokinetic characteristics of DMY in animal models and human body are also vital to the evaluation of their in vivo bioavailability efficacy.…”